STZ vs UTI
Constellation Brands vs Universal Technical Institute, Inc. — AI-powered side-by-side comparison
STZ
Constellation Brands
65
Buy
VS
UTI
Universal Technical Institute, Inc.
53
Watch
| Metric | STZ | UTI |
|---|
| AI Score |
65
|
53
|
| Price |
$133.88
|
$25.56
|
| P/E Ratio |
12.77×
|
40.60×
|
| ROE |
20.9%
|
19.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
52.6%
|
61.5%
|
| Debt / Equity |
1.28×
|
1.04×
|
| Dividend Yield |
3.1%
|
0.0%
|
| RSI (14) |
55.0
|
20.6
|
| Beta |
0.4
|
1.236
|
| Expected Upside |
+25.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for STZ versus UTI.
STZ leads by 12 points.
STZ scores 65/100 (Buy) versus UTI at 53/100 (Watch).
STZ Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is price structure making lower highs and lower lows. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 12.6 is inexpensive for the broad market — Value
- ROE of 23.1% shows genuine earnings power backing the valuation — Value
- Dividend yield of 3.1% pays you to wait — Value
Bear Case
- Revenue declining -10.0% YoY -- this is not a growth story right now — Growth
- Price structure making lower highs and lower lows — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
UTI Committee View
67% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Technical Analyst remains cautious — rsi at 21 is in oversold territory (could mean either capitulation or a bounce setup). This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Low leverage (debt-to-equity 0.27) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 37.4 is moderate-to-rich — Value
- Price-to-book of 5.4x prices in significant intangible value — Value
- EPS declining -25.9% YoY despite any revenue growth — Growth